Clinical Trial

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

Study acronym: CAMPR-II
Recruiting
View on ClinicalTrials.gov →
Summary
CAMPR-II Trial: A multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a saline-hydrated allogeneic dual-layer amniotic membrane product or a synthetic, resorbable polymeric wound matrix to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs
Trial Details
NCT Number NCT07701590
Lead Sponsor Capsicure, LLC
Collaborators: BioLab Holdings
Conditions Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Enrollment 147 participants
Start Date 2026-06-22
Primary Completion 2026-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-14